Survival of the fittest or best adapted: HLA-dependent tumor development

Giuseppe V. Masucci,1 Emilia Andersson,1 Lisa Villabona,1 Hildur Helgadottir,1 Kjell Bergfeldt,1 Federica Cavallo,2 Guido Forni,2 Soldano Ferrone,2 Aniruddha Choudhury,1 Barbara Seliger,2 Rolf Kiessling2
1Dept. Oncology-Pathology, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden;
2Molecular Biotechnology Center, Dept. of Clinical and Biological Sciences, University of Torino, Torino, Italy;
3University of Pittsburgh Cancer Institute, Departments of Surgery, Immunology and Pathology, School of Medicine, Pittsburgh, PA, USA;
4Institute of Medical Immunology, Martin Luther University Halle-Wittenberg, Halle/Saale, Germany

Abstract

The major histocompatibility complex (MHC) comprises a set of genes that are critical to immunity and surveillance against neoplastic transformation. There is increasing evidence that the MHC antigens not only regulate antitumor immune responses in experimental animal models but also correlate with survival and prognosis of patients with diverse types of cancers. MHC antigens may in the future function as potential biomarkers for prognosis and allow selection of cancer patients for intensive therapy.

Introduction

The recognition of antigenic peptides by CD8+ T lymphocytes in the context of major histocompatibility complex (MHC) class I and class II molecules on the surface of antigen-presenting cells is one of the initial steps that prime the adaptive immune system to respond to invading pathogens as well as potentially cancerous cells. The MHC class I molecules are, therefore, essential components of the adaptive immune system and critical to the immunological recognition of tumor cells. As a result, defects in the expression and/or function of MHC antigens allow tumor cells to escape from recognition and destruction by the host’s immune system.14

However, the number of studies analyzing associations between HLA frequency and cancer incidence, as well as prognosis, are still limited.

The major histocompatibility complex

In humans, the major histocompatibility complex is located on the short arm of chromosome 6 (6p21.3). It is one of the most intensively studied chromosomal regions in humans. Recently, the human genome has been depicted in block-like structures characterized by areas of high linkage disequilibrium (LD) creating so-called haplotype blocks, separated by regions of low LD, hypothesized to correspond to recombination hot spots.23 This arrangement greatly facilitates the discovery of genes that predispose individuals to diseases through ‘haplotype-tagging’ single-nucleotide polymorphism, reducing the number of markers needed in the mapping process.24 Haplotype blocks are an algorithmic definition of a region in the human genome characterized by reduced haplotype diversity or strong LD, rather than a biological phenomenon. The HLA loci typically span 3.6 Mb25 and extend to 7.6 Mb with the telomeric repeats. The adjacent sequences within the superlocus contain several genes regulating immune function and demonstrate synteny to the mouse MHC.26,27 About 28% of the expressed transcripts from the genes within the superlocus are potentially implicated in the immune response. For this reason, it is not unexpected that this genetic region is linked to a large number of autoimmune and immune-mediated diseases.28 One characteristic of the MHC loci is the high degree of LD found between alleles and the high degree of polymorphism within the genes encoding peptide-presenting molecules (HLA-DPB1, -DQB1, -DQA1, -DRB1, -C,-B and -A). "Ancestral haplotype" is a term used to describe conserved haplotypes that appear to be identical among individuals not known to be directly related. These ancestral haplotypes have a specific content of alleles at all MHC loci and have a particular genomic length. In the Caucasian population, some 30 ancestral haplotypes and recombinants among them account for almost 90% of the haplotypes found during genetic family studies.29

Association of MHC antigens with cancer prognosis

The association of HLA and cancer is now being established. Interestingly, none of the HLA (class I and II) alleles have been demonstrated to be associated with an increased incidence per se of any cancer. However, individual alleles are known to be overrepresented in certain cancers or correlate with survival or prognosis. The number of studies are still limited and predominantly describe HLA A*2 associated virus-related malignancies, such as in situ cancer of the vulva,30 cervical cancer31 and nasopharyngeal cancer.32

History of HLA and prognosis

In a study of 176 early-onset breast cancer patients and 215 ethnicity and age-matched controls, the HLA class II genes HLA-DRB1*0302 and HLA-DRB1*11 were absent or expressed at significantly lower frequency in the breast cancer patients suggesting that these two alleles may be “protective”.20 In contrast, expression of the HLA-DR17 gene in patients with ulcerative colitis associated with a higher risk of patients developing colorectal cancer. In this study, 114 ulcerative colitis patients or ulcerative colitis patients who had developed colorectal cancer were compared for expression of various HLA class II alleles. While the HLA DR17 gene was noted in a higher frequency in the ulcerative colitis-colorectal cancer patients, HLA DR7, -DR1 or -DQ5 alleles were noted at a significantly higher frequency in ulcerative colitis “control” cases that did not develop colorectal cancer.6 In another study, women carrying the HLA-DRB1*0301 allele exhibited an increased risk of developing cervical intraepithelial neoplasia when infected by HPV 16 and this allele was also overrepresented in cervical intraepithelial neoplasia grade III cases in comparison to cervical intraepithelial neoplasia grade II cases.8 The HLA class I allele A*02 was associated with a reduced risk and HLA-A*01 with an increased risk of developing EBV positive Hodgkin’s lymphoma.7 The HLA-A*02 allele is associated with poor prognosis in non-small cell lung can-
cer patients\(^1\) ovarian and prostate cancer and malignant melanoma\(^2\) while HLA-A*11 and DR6 were associated with poor survival in patients with head and neck tumors.\(^2\) Finally, HLA has been studied as a factor that could predict the response to immunological treatments, such as vaccine or cytokine therapy, especially in melanoma,\(^3\) renal cell carcinoma\(^4\) and chronic myelogenous leukemia.\(^5\)

**HLA-A2 and ancestral haplotypes as prognostic factors**

We have been studying the correlation of ancestral haplotypes as a prognostic factor in several different malignancies. HLA-A2 is independently a negative clinical prognostic factor in patients with advanced ovarian cancer.\(^6\) Moreover, an overrepresentation of the HLA-A2 phenotype was observed in both ovarian and prostate cancer in Swedish patients compared to the normal population. The higher frequency of this allele found in Scandinavian countries significantly decreases moving further south in Europe. In parallel, ovarian and prostate cancer mortality rates decrease with latitude and correlate with the demographic changes in HLA-A2 expression.\(^7\)

The relationship of HLA and cancer further extend the correlation of single alleles to cancer survival and prognosis. As described above, ancestral haplotypes represent clusters of alleles that occur at a higher frequency in certain populations than predicted. These ancestral haplotypes have been correlated with survival and prognosis in diverse malignancies. For example, the ancestral haplotype 8.1 (A*01-B*08-TNF-308A) is predictive for a shorter progression free and overall survival in non-Hodgkin’s lymphoma\(^8\) or in malignant melanoma.\(^9\) In another study performed by us, the ancestral HLA haplotype 62.1 ([A2] B15 Cw3 DRB1*04) in patients with advanced metastatic melanoma was studied. The effect of HLA types on prognosis defined by Kaplan-Meier and Cox-Mantel methods were analyzed in patients with stage III (n=26) or IV (n=65) melanoma: 62.1 ancestral haplotype in clinical stage IV patients was significantly and independently associated with a reduced survival rate from the time of appearance of metastasis (HR = 2.14; CI = 1.02-4.4; P=0.04) although the period from the primary diagnosis to metastasis was the longest in patients with this haplotype. Thus, melanoma patients in this cohort with the 62.1 ancestral haplotype which is associated with autoimmune diseases have an initial strong anti-tumor capacity with longer metastasis-free period but deteriorate rapidly when the disease advances.\(^10\)

**The hypotheses**

The disease progression seems to be predetermined by a somatic gene such as HLA-A2. At the genetic level one could consider a linkage to putative onco- or tumor suppressor genes. The HLA-locus at chromosome 6 is a region with high incidence of polymorphism and the classic illustration of linkage disequilibrium.\(^11\) One can thus imagine a genetic linkage to possible onco- or tumor suppressor genes present near the locus, i.e. CDKN1A/ p15/MAFI on 6p21, TFA, AP2 on 6p24. A linkage to an onco- or tumor suppressor gene could explain the increased potential for oncogenic transformation of cells and thus an increased mortality in these patients.

At the epigenetic level a microRNA-dependent downregulation of the MHC antigen expression in the HLA-A2 patients may be speculated. MicroRNAs (miRNAs) are an abundant class of small non-coding RNAs that function as gene regulators. Although deregulation of miRNA expression is involved in the initiation and progression of tumorigenesis, the underlying mechanisms of miRNA deregulation in human cancer are largely unknown. However, increasing evidence indicates that disturbance in the miRNA biogenesis machinery contributes to miRNA deregulation in human cancer.\(^12\) Reports of miRNA regulation of HLA-G expression have been recently published.\(^13\) In addition, a specific miRNA has been identified for HLA-A2 (miR181a),\(^14\) which incidentally is also reported to have tumor suppressor properties.\(^15\) During the initial process of oncogenesis, transformed cells may up-regulate transcription of the MHC genes which serve to absorb and engage the pool of miRNA. Potentially, this may prevent translation of MHC antigen message which impedes expression of MHC antigen and immune recognition. Moreover, normal regulatory functions of the miRNA are also compromised as the “decoy” transformed cells absorb and engage the available pool of miRNA. This sponge or decoy effect has been used as a method to study the function of miRNAs.\(^16\) On the other hand, it is still unknown whether this can occur naturally in a cell. Nevertheless, the above model could potentially explain the more progressing disease and poorer prognosis in HLA-A2 positive patients.

**Tumor escape, HLA expression and the antigen processing machinery**

**The escape**

Despite the attraction of T-cell based immunotherapies during the last decade, the clinical responses were effective only in a minority of immunized patients without a correlation between the induction of T-cell and clinical responses.\(^17\) These insufficient results may be due to tumor immune escape mechanisms. A number of distinct immune evasion strategies have been identified in tumors, which include defects in interferon signal transduction pathways, lack of co-stimulatory molecules and presence of co-inhibitory molecules, as well as HLA class I antigen processing machinery (APM) abnormalities, including haplotype loss.\(^18\) The impaired antigen processing and presentation lead to a reduced recognition of the HLA class I/p2-microglobulin(p2-m)-peptide complex by CD8+ cytotoxic T lymphocytes.\(^19\) Furthermore, in some malignancies the frequency of HLA class I APM downregulation is associated with higher grading, staging, aggressive histology and abnormal DNA content of tumors, which is often more pronounced in metastases when compared to primary lesions and associated with a reduced patients’ survival.\(^20\) Matsushita et al.\(^21\) found that a strong HLA-DR-positive expression on colorectal cancer cells was significantly related to better prognosis for the cancer patients. They have also suggested a possible role for c-myc and propose that HLA DR is up-regulated while c-myc is suppressed by interferon gamma (IFN-γ), thus decreasing levels of c-myc in cancer tissue with high levels of IFN-γ.

**Non-classical MHC**

HLA-E, -F and -G are non-classical MHC loci; the trans-membrane heavy chain class Ib and the association with the light chain β2-microglobulin are their common characteristics.\(^22\) HLA-G is physiologically involved in the regulation of fetal immunological escape from maternal immune surveillance and at low levels or in its absence is known to be associated with pre-eclampsia and spontaneous abortions.\(^23\) HLA-G is expressed in both membrane bound and soluble forms and has been described to function both as a tumour marker and in immune tolerance. Instead of interacting with a classical MHC molecule, HLA-G associates with a KIR on NK cells and the CD94/NKG2 receptor on T cells. Most KIRs recognize HLA-G on the surface of cells infected with HBV or HCV. The binding of KIRs to HLA-G is also associated with a reduced patients’ survival.\(^24\) Therefore, HLA-G could be a promising target for immunotherapy.\(^25\) HLA-G binds directly to the inhibitory receptors ILT-2 on B, NK and T-cells, ILT-4 on macrophages, KIR2DL4 on NK cells and CD55 on endothelial, NK and T cells. HLA-G inhibits NK and T-cell mediated cell lysis and it can also induce CD4 positive T cell anergy and long-term immunotolerance.\(^26\) HLA-G is expressed by advanced ovarian cancer of aggressive histology and also correlates to a significantly worse prognosis in ovarian carcinoma.\(^27\) HLA-E may contribute to tumors escaping from immune surveillance by inhibiting NK cell-mediated lysis, since it is recognized by the CD94/NKG2 receptor on NK cells.\(^28\) Through highly specific peptide binding groove adapted to conserved leader sequence peptides on the HLA-E molecule, the NK cells are able to recognize cellular expression of

---

**[Journal of Nucleic Acids Investigation 2010; 1:e9]**

**[page 42]**
other MHC class I molecules. HLA-E has been described as being over-expressed in several human cancers, particularly in colorectal cancer specimens that have decreased infiltration of NK cells as well as shorter disease-free survival.69

Class I-like genes: MICA/MICB

The MHC class Ic-related genes A and B, MICA and MICB do not present peptides and are not associated with β2-microglobulin.70 Instead MICA and MICB are polymorphic cosubstituting ligands for the receptor NKGD2D on NK cells, CD8+ T cells and gamma/delta T cells and may activate both innate and adaptive immunity.71 MICA and MICB are present on the surface of many tumors and potentially may stimulate immune responses but can be downregulated by microRNA.72 Soluble MICA shed by tumor cells can bind to NKGD2D receptor on NK and T cells without triggering downstream signals and induce degradation of the NKGD2D receptor on the immune effector cells.73

Internalization of the complex also may result in expansion of immunosuppressive NKGD2D/CD4+ T cells. There are potentially ligand-receptor interactions other than NKGD2D that may also contribute to suppression of proliferating T cells.74

The APM complex

The APM complex, which mediates the interaction of tumor cells with HLA class I antigen restricted, tumor antigen (TA)-specific cytotoxic T lymphocytes, is generated through several steps with the participation of different molecules. Briefly, 9-11 amino acid-long peptides are derived from the cleavage of mostly, although not exclusively, endogenous cytosolic and nuclear proteins. The cleavage is executed by the constitutive and IFN-γ inducible proteasome subunits as well as by other aminopeptidases.75 Peptides are then translocated via the heterodimeric transporter-associated with antigen processing (TAP) complex from the cytosol into the endoplasmic reticulum (ER), where they are loaded with the help of the chaperones calnexin, calreticulin, ERP57 and tapasin (tpn) onto β2 microglobulin (β2 m)-HLA class I heavy chain (HC) complexes. The assembled trimeric HLA class I-peptide complex is released from the peptide-loading complex and transported via the trans Golgi apparatus to the cell surface for presentation to CD8+ cytotoxic T lymphocytes.76

Defects in APM component expression

The recently described positive outcome of a clinical trial with T-cell based immunotherapy in prostate cancer has stimulated interest in the characterization of the APM component expression in prostate cancer lesions, since

The downregulation of HLA expression by oncogenes: the paradigm of HER-2/neu

HER-2/neu is a 185-kDa glycoprotein member of the epidermal growth factor receptor (EGFR) family of tyrosine kinases and considered one of the most attractive targets for immunotherapeutic interventions.86 This oncogene is selectively over-expressed in a broad variety of human tumors, including 25-40% of breast, head and neck cancer, ovarian, gastric, renal, esophageal and colorectal carcinomas, and a small proportion of human melano-
momas.15,87-92 HER-2/neu can be regarded as an indispensable tumor antigen, since tumours over-expressing HER-2/neu are dependent on this oncogene for their survival and silencing consequently leads to growth arrest and/or apoptosis induction.83,85 This phenomenon is called “oncogene addiction”, where a single oncogene can impair the growth and survival of cancer cells in spite of the fact that these cells contains a complexity of genetic and epigenetic abnormalities.85 It is well known that HER-2/neu expression is associated with a reduced MHC class I surface antigen expression.88,90 HER-2/neu over-expression in murine and human tumor cells caused abnormalities of MHC class I surface expression due to impaired APM component expression, including LMPs, TAP and the chaperone tapasin, whereas the expression of MHC class I heavy chain as well as β2 m were only marginally affected. This HER-2/neu-mediated deficient APM component expression could be reverted by IFN-γ treatment suggesting a deregulation rather than structural alterations as underlying molecular mechanisms of their deficient expression. In order to determine the mode of regulation, the transcriptional activity of APM components was analyzed in HER-2/neu- and HER-2/neu+ cells using APM-specific promoter assays. All major APM components were transcriptionally down-regulated in HER-2/neu+ when compared to HER-2/neu cells, which was accompanied by a reduced binding of RNA polymerase II to the APM promoters. Site-directed mutagenesis of p300, as well as the
proximal and distal E2F1 transcription factor binding sites at position -146, and -229, resulted in a restoration of the tapasin promoter activity in HER-2/neu+ cells compared to that of wild-type promoter activity in untransformed HER-2/neu fibroblasts. Moreover, siRNA-mediated silencing of transcription factor 1 (E2F1) is associated with an increased tapasin expression. These data suggest that a distinct expression pattern of transcription factors are involved in the suppression of APM-specific promoters and thus provides a novel route for intervention of HER-2/neu+ tumors (Bukur and Seliger, personal communication, 2010).

Conclusions

The MHC is remarkable in its profound impact on human diseases and its intriguing complexity with polymorphisms, duplications, insertions, deletions and yet strongly conserved blocks, known as ancestral haplotypes. Only recently has the role of HLA in cancer been established, considering that some haplotypes are connected to prognosis and survival in different types of cancer. The traditional role of MHC genes has been thought to be as signals for the cellular immune system and NK cells to recognize infected or neoplastic target cells. Recently, however, the non-coding sequences have gained more interest and the possibility of occult regulators of oncogenesis within this region is being examined. Attempts to link different HLA haplotypes to known oncogenes are also being carried out. One question that has only partly been addressed is the consequences of the high copy numbers of many MHC genes. The function of one gene may very well be counteracted on an epigenetic level if the same gene is duplicated or multiplied. Another issue is that haplotypes that are associated with poor prognosis in one malignancy are said to be protective in another.

One of the challenges in management of cancer patients is the limited knowledge of prognostic factors in patients with metastatic disease that predict their outcome following conventional therapy with surgery, radiation and chemotherapy. Our investigations validate the hypothesis that HLA typing of patients may provide additional information to predict treatment response in patients with advanced disease. HLA typing might be a valuable tool to delineate patients who would benefit the greatest from aggressive regimes from those who have no additional benefit and increased adverse effects from more aggressive regimes. Additional therapeutic modalities that impede immune escape by tumors through downregulation of HLA expression may also increase the survival and prognosis of advanced cancer patients when utilized in combinatorial therapy approaches.

Figure 1. The population of healthy individuals (left upper corner) presents a normal distribution of HLA haplotypes (red spots = HLA A2 or AHHS; green spots = others) when mapped against the theoretical risk of developing cancer (e.g. EOC, prostate cancer or malignant melanoma). No associations are noted. Following diagnosis (center) a significant number of those cases have long-term remissions or slow progressions (low left corner). The other group (red spots) have treatment-refractory and more aggressive disease. These patients demonstrate an increased frequency of HLA A2 and AHHS.

References

2. Sioud M. Does our current understanding of immune tolerance, autoimmunity, and immunosuppressive mechanisms facilitate the design of efficient cancer vaccines? Scan J Immunol 2009;70:516–25.
12. consortium TMs. Complete sequence and gene map of a human major histocompati-
bility complex. The MHC sequencing con-
gen polymorphism and human papillo-
33. Somman JA, Unger JM, Liu PY, et al. Adjuvant immunotherapy of resected, inter-
34. Bain C, Merrouche Y, Puisieux I, et al. Correlation between clinical response to interleukin 2 and HLA phenotypes in patients with metastatic renal cell carci-
38. De Petris L, Bergfeldt K, Hising C, et al. Correlation between HLA-A2 gene frequen-
42. Castelli EC, Moreau P, Oya E, et al. In silico analysis of microRNAs targeting the HLA-G 3’ untranslated region alleles and haplo-
44. Wang X, Gocnek E, Liu CG, et al. Micro-
RNAs181 regulate the expression of p27Kip1 in human myeloid leukemia cells induced to differentiate by 1,25-dihydroxyvi-
45. Brown BD, Naldini L. Exploiting and antag-
onizing microRNA regulation for therapeu-
46. Chan JK, Loizzi V, Magistris A, et al. Differences in prognostic molecular mark-
49. Norell H, Carlsen M, Ohlum T, et al. Frequent loss of HLA-A2 expression in metastasizing ovarian carcinomas associat-
50. Johnsen HE, Hutchings M, Taaning E, et al. Selective loss of progenitor subsets follow-
ing clinical CD34+ cell enrichment by mag-
etic field, magnetic beads or chromatogra-
phy separation. Bone Marrow Transplant 1999;24:1329-36.
52. Han LY, Fletcher MS, Urbauer DL, et al. HLA class I antigen processing machinery com-
ponent expression and intratumoral T-Cell infiltrate as independent prognostic mark-
ers in ovarian carcinoma. Clin Cancer Res


